Placeholder

Topoisomerase Inhibitors – Pipeline Insights, 2015

$1250 - $4000

Release Date

31-12-2015

Delivery Format

PDF

Geographical Coverage

Worldwide

Pricing

Enquire for discount Inquiry Before Buying

Summary
DelveInsight’s, Topoisomerase Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Topoisomerase Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Topoisomerase Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Topoisomerase Inhibitors- Pipeline Insights, 2015 Report covers the Topoisomerase Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Topoisomerase Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Topoisomerase Inhibitors.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– DelveInsight’s report provides a Topoisomerase Inhibitors Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
– Coverage of the Topoisomerase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Topoisomerase Inhibitors and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Topoisomerase Inhibitors
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Track your competitors and develop strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
– Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

• Topoisomerase Inhibitors Overview
• Topoisomerase Inhibitors Disease Associated
• Topoisomerase Inhibitors Pipeline Therapeutics
• Topoisomerase Inhibitors Therapeutics under Development by Companies
• Topoisomerase Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Topoisomerase Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Topoisomerase Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Topoisomerase Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Topoisomerase Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Topoisomerase Inhibitors – Discontinued Products
• Topoisomerase Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Topoisomerase Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Topoisomerase Inhibitors by Therapy Area, 2015
• Number of Products under Development for Topoisomerase Inhibitors, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Topoisomerase Inhibitors Assessment by Monotherapy Products
• Topoisomerase Inhibitors Assessment by Combination Products
• Topoisomerase Inhibitors Assessment by Route of Administration
• Topoisomerase Inhibitors Assessment by Stage and Route of Administration
• Topoisomerase Inhibitors Assessment by Molecule Type
• Topoisomerase Inhibitors Assessment by Stage and Molecule Type
• Topoisomerase Inhibitors Therapeutics – Discontinued Products
• Topoisomerase Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015• Number of Products under Development for Topoisomerase Inhibitors by Therapy Area, 2015
• Number of Products under Development for Topoisomerase Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Topoisomerase Inhibitors Assessment by Monotherapy Products
• Topoisomerase Inhibitors Assessment by Combination Products
• Topoisomerase Inhibitors Assessment by Route of Administration
• Topoisomerase Inhibitors Assessment by Stage and Route of Administration
• Topoisomerase Inhibitors Assessment by Molecule Type
• Topoisomerase Inhibitors Assessment by Stage and Molecule Type

This healthcare and pharma insights & market research report requires few ‘real-time updates’, in addition to all readily available information, which may take 48 to 72 hours (excluding weekends and public holidays) of processing and complete report delivery after placing an order.

Category

Publisher

DelveInsight